Rob is a Senior Partner with Takeda Ventures Inc. (TVI) and is based in London, UK. He serves as a director or observer on the boards of seven TVI portfolio companies, including Emendo Bio Inc, BioMx Ltd. and Hookipa Pharma (Nasdaq: HOOK). Prior to TVI, Rob was Director of Healthcare Investments at Touchstone Innovations. Whilst there, he served on the board of seven Touchstone portfolio companies, including Stanmore Implants Ltd (acquired by Stryker), and played a key role in the funding and/or founding of five companies. Rob was previously Principal in the life science team at Sofinnova Partners, a leading European venture capital firm. While at Sofinnova, Rob was actively involved in seven investments, five of which were acquired or listed. Rob’s experience ranges from technology transfer with Cancer Research Technology (CRUK) through to pharmaceutical consultancy with IMS Health. He holds an MSc in Biochemistry from the University of Oxford and a PhD in Oncology from the University of Cambridge.
Kevin is a Venture Partner at SV Health Investors and President and CEO of Enara Bio. Prior to joining SV, Kevin was Chief Strategy and Business Officer and a member of the executive leadership team at Immunocore Ltd. In this role, he was responsible for shaping the company’s corporate, R&D and growth strategies, as well as for overseeing business development. Kevin was also co-head of the company’s Infectious Disease Unit and helped lead the Bill & Melinda Gates Foundation investment of up to $40 million. Prior to joining Immunocore, Kevin was President, Chief Executive Officer of Quartet Medicine, a company he co-founded in late 2013 while working as an Entrepreneur-in-Residence at Atlas Ventures. Kevin was also the Chief Operating Officer of Annovation Biopharma, another Atlas Ventures-funded company, which was sold to the Medicines Company in January 2015. He has also held senior executive R&D and corporate development roles at several venture capital-backed companies, including Vice President of Corporate Development at Kala Pharmaceuticals (NASDAQ:KALA) and, earlier in his career, spent time as an investment associate at PureTech Health (LSE: PRTC) an early stage venture capital firm. Kevin holds a BA from the University of Colorado Boulder, and a PhD from the Massachusetts Institute of Technology.
Caroline is a principal with Lightstone Ventures based out of the firm’s Dublin office. She serves as a director or observer on the boards of ALX Oncology, Carrick Therapeutics, Cerevance, and FIRE-1. Prior to Lightstone, Caroline consulted for multiple biopharma and medtech start-ups. Prior to that, she served on the board of senior management for Bayer Ltd. Ireland as head of market access and reimbursement and was responsible for health economics, health technology assessment applications and reimbursement/pricing negotiations for new drugs. Prior to Bayer, Caroline held roles in regulatory affairs, product management, marketing and strategic business development. Caroline holds a BS in Pharmacy from Trinity College Dublin, MS in Pharmaceutical Medicine from Trinity College Dublin, and an MS in BioInnovation from National University of Ireland, Galway.
Maina is a partner with Sofinnova Partners. Maina joined the firm in 2018 and has a long track record as a successful healthcare investor. Prior to joining Sofinnova Partners, she was Director of Healthcare Investment at Touchstone Innovations (formerly Imperial Innovations) in London (UK), where she led or co-led investments in the UK. Previously, she worked in the R&D teams of several UK and US biotech companies, including Celltech, Oxford Glyco Sciences, Chimeric Therapies and GeneMedicine. Maina holds a BS from the University of Texas at Austin and an MBA from the Imperial Business School. Maina’s current investments include Sitryx Therapeutics, Cincor, and Enyo Pharma.
Houman is a Managing Partner at SV Health Investors based out of their London offices. He has founded seven SV companies: Mestag Therapeutics, Sitryx Therapeutics, Enara Bio, Zarodex Therapeutics, TrexBio, Alchemab Therapeutics and Cellinta. Houman is also a member of the Investment Committee for the Dementia Discovery Fund and serves as a Director of Karus Therapeutics. Most recently, Houman was Vice President and Head of the Clinical Science group with UCB. Prior to joining UCB, he co-founded and served as a Director for both Cardiac Report and Heart Metabolics. He is Visiting Professor and Head of Experimental Therapeutics at the University of Oxford. Following his cardiology training, Houman was appointed as an honorary Consultant Cardiologist at the John Radcliffe Hospital in Oxford. Houman holds a BM BCh and a DPhil from the University of Oxford.